Document is current
Any future updates will be listed below
-
Authors
Leo, Fabian
Polsfuss, Silke
Przewosnik, Anne-Sophie
Grohé, Christian
Lange, Christoph
-
Funding
Funding for this research was provided by:
Forschungszentrum Borstel - Leibniz Lungenzentrum
- License Information
-
More Information
Article History
Received: 27 September 2025
Accepted: 8 December 2025
First Online: 17 December 2025
Declarations
:
: Written informed consent was obtained from the patient before writing this report.
: The patient gave her written consent to the publication of her personal and clinical details, including medical images.
: C.L. is supported by the German Center of Infection Research. F.L. and C.L provided consultation service to Insmed , a biopharmaceutical company that produces liposomal amikacin inhalation suspension for the treatment of NTM pulmonary disease. F.L., S.P. and C.L. received speakers honoraria from this company, outside the scope of this work. A.S.P. and C.G. declare no competing financial or non-financial interests.
